Literature DB >> 15190396

Injection of botulinum toxin A to the upper esophageal sphincter for oropharyngeal dysphagia in two patients with inclusion body myositis.

Louis W C Liu1, Mark Tarnopolsky, David Armstrong.   

Abstract

Inclusion body myositis (IBM) is a progressive degenerative skeletal muscle disease leading to weakening and atrophy of both proximal and distal muscles. Dysphagia is reported in up to 86% of IBM patients. Surgical cricopharyngeal myotomy may be effective for cricopharyngeal dysphagia and there is one published report that botulinum toxin A, injected into the cricopharyngeus muscle using a hypopharyngoscope under general anesthesia, relieved IBM-associated dysphagia. This report presents the first documentation of botulinum toxin A injection into the upper esophageal sphincter using a flexible esophagogastroduodenoscope under conscious sedation, to reduce upper esophageal sphincter pressure and successfully alleviate oropharyngeal dysphagia in two IBM patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15190396     DOI: 10.1155/2004/360537

Source DB:  PubMed          Journal:  Can J Gastroenterol        ISSN: 0835-7900            Impact factor:   3.522


  18 in total

1.  A case of inclusion body myositis responsive to prednisolone therapy.

Authors:  Rahul Kalla; Majella Soumakiyan; Stephen Tuck
Journal:  Clin Rheumatol       Date:  2008-12-06       Impact factor: 2.980

Review 2.  Update on treatment of inclusion body myositis.

Authors:  Maren Breithaupt; Jens Schmidt
Journal:  Curr Rheumatol Rep       Date:  2013-05       Impact factor: 4.592

3.  Botulinum toxin and rehabilitation treatment in inclusion body myositis for severe oropharyngeal dysphagia.

Authors:  Chiara Di Pede; Stefano Masiero; Valentina Bonsangue; Rosario Marchese Ragona; Alessandra Del Felice
Journal:  Neurol Sci       Date:  2016-04-20       Impact factor: 3.307

4.  Dysphagia in inflammatory myopathy: self-report, incidence, and prevalence.

Authors:  Kylie Patricia Mulcahy; Patricia Claire Langdon; Francis Mastaglia
Journal:  Dysphagia       Date:  2011-03-27       Impact factor: 3.438

5.  Pharyngeal dysphagia in inflammatory muscle diseases resulting from impaired suprahyoid musculature.

Authors:  P Claire Langdon; Kylie Mulcahy; Kelly L Shepherd; Vincent H Low; Frank L Mastaglia
Journal:  Dysphagia       Date:  2011-12-30       Impact factor: 3.438

6.  Gastrointestinal Uses of Botulinum Toxin.

Authors:  Maria Cariati; Maria Michela Chiarello; Marco Cannistra'; Maria Antonietta Lerose; Giuseppe Brisinda
Journal:  Handb Exp Pharmacol       Date:  2021

Review 7.  Botulinum toxin for gastrointestinal disorders: therapy and mechanisms.

Authors:  H Vittal; P F Pasricha
Journal:  Neurotox Res       Date:  2006-04       Impact factor: 3.911

8.  Safety of botulinum toxin for dysphagia in oculopharyngeal muscular dystrophy.

Authors:  Sarah Youssof; Ronald M Schrader; Carol Romero-Clark; Gulmohor Roy; Michael Spafford
Journal:  Muscle Nerve       Date:  2014-02-25       Impact factor: 3.217

9.  Botulinum toxin injection for the treatment of upper esophageal sphincter dysfunction.

Authors:  Elizabeth A Kelly; Ian J Koszewski; Safwan S Jaradeh; Albert L Merati; Joel H Blumin; Jonathan M Bock
Journal:  Ann Otol Rhinol Laryngol       Date:  2013-02       Impact factor: 1.547

Review 10.  Diagnosis, pathogenesis and treatment of myositis: recent advances.

Authors:  P-O Carstens; J Schmidt
Journal:  Clin Exp Immunol       Date:  2014-03       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.